1. Chen L, Kumar S, Wu H. A review of current antibiotic resistance and promising antibiotics with novel modes of action to combat antibiotic resistance. Arch Microbiol 2023; 205(11): 356.
2. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century–a clinical super-challenge. N Engl J Med 2009; 360(5): 439-43.
3. Zhang S, Liao X, Ding T, Ahn J. Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria. Antibiotics (Basel) 2024; 13(3): 260.
4. Miller LA, Ratnam K, Payne DJ. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001; 1(5): 451-8.
5. Bush K, Bradford PA. Interplay between β-lactamases and new β-lactamase inhibitors. Nat Rev Microbiol 2019; 17(5): 295-306. Erratum in: Nat Rev Microbiol 2019; 17(7): 459-460.
6. Kang SJ, Kim DH, Lee BJ. Metallo-β-lactamase inhibitors: A continuing challenge for combating antibiotic resistance. Biophys Chem 2024; 309: 107228.
7. Lee N, Yuen KY, Kumana CR. Clinical role of beta-lactam/beta-lactamase inhibitor combinations. Drugs 2003; 63(14): 1511-24.
8. Aktaş F. Beta Laktam- Beta Laktamaz İnhibitörü Antibiyotiklerin Klinik Kullanımı (II). Piperasilin- Tazobaktam, Tikarsilin- Klavulanik Asit ve Sefoperazon? Sulbaktam’ın Klinik Kullanım-
ları. Türkiye Klinikleri J Pharmacol-Special Topics 2004; 2(2): 123-7.
9. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010; 23(1): 160-201.
10. Todd PA, Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990; 39(2): 264-307.
11. Evans J 2023, Evans J, Hanoodi M, Wittler M. Amoxicillin Clavulanate. [Updated 2023 Aug 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK538164/.
12. Veeraraghavan B, Bakthavatchalam YD, Sahni RD. Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy. Infect Dis Ther 2021; 10(1): 15-25.
13. Sili U, Mert A. 1986’dan 2010’a beta-laktamaz inhibitörleri. ANKEM Derg 2010; 24(Ek2): 28-32.
14. McCormack PL, Keating GM. Amoxicillin/clavulanic acid 2000 mg/125 mg extended release (XR): a review of its use in the treatment of respiratory tract infections in adults. Drugs 2005;
65(1): 121-36.
15. Doi Y. Penicillins and β-Lactamase Inhibitors. In: Bennett J, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases Electronic. Available from: Elsevier eBooks+,
9th Edition, Elsevier-OHCE, 2019, chapter:20, pp.251-268.
16. Rodríguez-Guardado A, Blanco A, Cartón JA. Ampicillin/Sulbactam in Combination: A Review of its Use in the Treatment of Severe Bacterial Infections. Clinical Medicine Reviews in The-
rapeutics 2010; 2: 1–13.
17. Akova M. Sulbactam-containing beta-lactamase inhibitor combinations. Clin Microbiol Infect 2008;14 Suppl 1: 185-8. Erratum in: Clin Microbiol Infect 2008; 14 Suppl 5: 21-4.
18. Alfei S, Schito AM. β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources. Pharmaceuticals (Basel) 2022; 15(4): 476.
19. Rafailidis P, Panagopoulos P, Koutserimpas C, Samonis G. Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections.
Antibiotics (Basel) 2024; 13(3): 261.
20. Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by
prolonged infusion in obese patients. Int J Antimicrob Agents. 2013; 41(1): 52-6.
21. Tamma PD, Han JH, Rock C, Antibacterial Resistance Leadership Group, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients
with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 2015; 60: 1319–1325.
22. Rando E, Salvati F, Sangiorgi F, Catania F, Leone E, Oliva A, et al. Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream
infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study. J Antimicrob Chemother 2024;79(2): 453-461.
23. Wise R, Logan M, Cooper M, Andrews JM. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 1991; 35(6):
1081-4.
24. Sörgel F, Kinzig M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med 1994; 20: 4-20.
25. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007; 5(3): 365-
83.
26. Martin-Loeches I, Bruno CJ, DeRyke CA. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence. Future Microbiol 2024 Jan 22.
27. Farrell DJ, Sader HS, Flamm RK, et al. Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in US and European medical
centres (2012). Int J Antimicrob Agents 2014; 43: 533–539.
28. Chaïbi K, Jaureguy F, Do Rego H, Ruiz P, Mory C, El Helali N, Mrabet S, Mizrahi A, Zahar JR, Pilmis B. What to Do with the New Antibiotics? Antibiotics (Basel) 2023; 12(4): 654.
29. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effecti-
veness and evolution of resistance. Clin Infect Dis 2017; 65: 110–120.
30. Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P. In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during
2014–2015. Antimicrob Agents Chemother 2019; 63: e00514-19.
31. Tselepis L, Langley GW, Aboklaish AF, Widlake E, Jackson DE, Walsh TR, et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive
and carbapenemase-producing Enterobacteriaceae. Int J Antimicrob Agents 2020; 56: 105925.
32. Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, et al. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With
Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. JAMA 2022; 328(13): 1304-1314.
33. Marino A, Campanella E, Stracquadanio S, Calvo M, Migliorisi G, Nicolosi A, et al. Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections:
A Narrative Review, Clinical Considerations, and Expert Opinion. Antibiotics (Basel) 2023; 12(10): 1521.
34. Shirley M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs 2018; 78(6): 675-692.
35. Aslan AT, Akova M. The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations. Antibiotics (Basel) 2022; 11(2): 277.
36. Bologna E, Licari LC, Manfredi C, Ditonno F, Cirillo L, Fusco GM, et al. Carbapenem-Resistant Enterobacteriaceae in Urinary Tract Infections: From Biological Insights to Emerging Thera-
peutic Alternatives. Medicina (Kaunas) 2024; 60(2): 214.
37. Principe L, Lupia T, Andriani L, Campanile F, Carcione D, Corcione S, et al. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lacta-
mase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians. Pharmaceuticals (Basel) 2022; 15(4): 463.
38. Zasowski EJ, Rybak JM, Rybak MJ. The β-lactams strike back: ceftazidime-avibactam. Pharmacotherapy 2015; 35: 755–770.
39. https://www.ema.europa.eu/en/documents/product-information/emblaveo-epar-product-information_en.pdf., Emblaveo: EPAR-Product information, 27 Mayıs 2024’de indirildi.
40. Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L. The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic
Review of In Vitro Studies and Clinical Cases. Antibiotics (Basel) 2021; 10(8): 1012.
41. Timsit JF, Wicky PH, de Montmollin E. Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients. Antibiotics (Basel) 2022; 11(2): 144.
42. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative
Infections. Clin Infect Dis 2023 Jul 18:ciad428.
43. O’Donnell JN, Lodise TP. New Perspectives on Antimicrobial Agents: Imipenem-Relebactam. Antimicrob Agents Chemother 2022; 66(7): e0025622.
44. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Com-
binations. Drugs 2018; 78(1): 65-98.
45. Sansone P, Giaccari LG, Di Flumeri G, Pace MC, Pota V, Coppolino F, et al. Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence. Life (Basel) 2024; 14(5): 614.
46. Keam SJ. Sulbactam/Durlobactam: First Approval. Drugs 2023; 83(13): 1245-1252.
47. Fratoni AJ, Berry AV, Liu X, Chen X, Wu Y, Nicolau DP, et al. Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-nega-
tive bacteria: a novel modelling approach for time-dependent killing. J Antimicrob Chemother 2023; 78(9): 2343-2353.
48. Vabomere (Meropenem and Vaborbactam) for Injection; Approval by FDA’s Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/Drugsatfda_docs/Label/2017/209776lbl.
pdf. 14 Mayıs 2024’te indirildi.
49. https://www.ema.europa.eu/en/documents/overview/vabomere-epar-medicine-overview_en.pdf. 14 Mayıs 2024’te indirildi.
50. Duda-Madej A, Viscardi S, Topola E. Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance. Antibiotics (Basel) 2023;
12(11): 1612.
51. Barbier F, Hraiech S, Kernéis S, Veluppillai N, Pajot O, Poissy J, et al. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically
ill patients. Ann Intensive Care 2023; 13(1): 65.
52. Forteza Guillot M, Martín Cerezuela M, Ramírez P. New evidence in severe pneumonia: meropenem-vaborbactam. Rev Esp Quimioter 2022; 35 (Suppl 1): 43-45.
53. McGovern PC, Wagenlehner F, Gasink L, Moeck G, McLeroth PL, Beth M, et al. 731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of
Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP). Open Forum Infect Dis 2022;9 (Suppl 2): ofac492.022.
54. Lomovskaya O, Tsivkovski R, Sun D, Reddy R, Totrov M, Hecker S, et al. QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Bioche-
mical and Microbiological Characteristics. Front Microbiol 2021; 12: 697180.
55. Griffith D, Roberts J, Wallis S, Hernandez-Mitre MP, Morgan E, Gehrke S, et al. 216. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase
inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects. Open Forum Infect Dis 2022; 9(Suppl 2): ofac492.294.
56. Griffith D, Roberts J, Wallis S, Hernandez-Mitre MP, Morgan E, Dudley M, et al. 218. A phase 1 study of the single-dose safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor
xeruborbactam administered as the isobutyryloxymethyl oral prodrug to healthy adult subjects. Open Forum Infect Dis 2022; 9 (supplement 2): ofac492.296.